Article: Idle plant revs up.

Byline: Andrea L. Stape

Jul. 14--As it works to grow a biotechnology industry, Rhode Island put another check in the win column yesterday after Alexion Pharmaceuticals Inc. announced its purchase of an idle drug manufacturing plant in Smithfield.

Connecticut-based Alexion, a drug development company, bought Dow Chemical's former plant to produce Soliris, a drug for treating a rare genetic blood disorder. Alexion plans to have at least 80 employees staffing the facility.

The company did not release the plant's sale price.

Alexion will remain headquartered in Cheshire, Conn., but expects to start producing the drug in the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!